Brolucizumab-Dbll vs Tarcocimab tedromer
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Age-Related Macular Degeneration
Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline
Brolucizumab-Dbll
Marketed by Novartis and partners
NCT05672979 · Phase 3 · status unknown
This is a single-arm, unblinded study with no placebo or active comparator, so it cannot establish how much of any visual acuity change is attributable to brolucizumab itself. Results are not yet available.
No aligned efficacy figure on record for this race.
Tarcocimab tedromer
Developed by Kodiak Sciences Inc.
NCT06556368 · Phase 3 · active, not recruiting
This was a randomized, quadruple-masked Phase 3 trial with 675 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-09-28. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.
Reported efficacy
Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to the Average of Non-missing BCVA Values of Weeks 40, 44 and 48. (Day 1 to Week 48): Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to the Average of Non-missing BCVA Values of Weeks 40, 44 and 48. (Day 1 to Week 48): KSI-301 (Treatment Group A) 2.5 ETDRS Letters (Standard Error 0.78) vs Aflibercept (Treatment Group B) 4.6 ETDRS Letters (Standard Error 0.76) (met)
Result source: NCT04964089
Results for Age-Related Macular Degeneration
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Brolucizumab-Dbll: registry results are on file for Age-Related Macular Degeneration, but their comparison mappings are not yet available.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Tarcocimab tedromer
+ 68 further endpoints in the CSV export.
Available safety results
Tarcocimab tedromer
| Dropout rate | 8.3% NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 |
|---|---|
| Discontinued due to AEs | 2.9% NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 |
| Serious AEs | 14.1% NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 |
| Most frequent reported AEs | covid-19 12.3% neovascular age-related macular degeneration - fellow eye 8% vitreous floaters - study eye 7.6% NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 |
Wet Age-Related Macular Degeneration
Shared mechanism: VEGF-A · full Wet Age-Related Macular Degeneration pipeline
Brolucizumab-Dbll
Marketed by Novartis and partners
NCT02307682 · Phase 3 · completed
Randomized, double-blind, active-controlled Phase 3 trial in 1,078 treated patients with neovascular AMD; the primary endpoint was change in best-corrected visual acuity at 48 weeks. Both brolucizumab doses met the prespecified non-inferiority margin versus aflibercept (3 mg difference -0.6 letters, 95% CI -2.5 to 1.3; 6 mg difference -0.2 letters, 95% CI -2.1 to 1.8; margin 4 letters), providing strong comparative evidence that brolucizumab is not worse than aflibercept on this functional endpoint.
No aligned efficacy figure on record for this race.
Tarcocimab tedromer
Developed by Kodiak Sciences Inc.
NCT06556368 · Phase 3 · active, not recruiting
This was a randomized, quadruple-masked Phase 3 trial with 675 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-09-28. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.
Reported efficacy
Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to the Average of Non-missing BCVA Values of Weeks 40, 44 and 48. (Day 1 to Week 48): Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to the Average of Non-missing BCVA Values of Weeks 40, 44 and 48. (Day 1 to Week 48): KSI-301 (Treatment Group A) 2.5 ETDRS Letters (Standard Error 0.78) vs Aflibercept (Treatment Group B) 4.6 ETDRS Letters (Standard Error 0.76) (met)
Result source: NCT04964089
Results for Wet Age-Related Macular Degeneration
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Brolucizumab-Dbll: registry results are on file for Wet Age-Related Macular Degeneration, but their comparison mappings are not yet available.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Tarcocimab tedromer
+ 68 further endpoints in the CSV export.
Available safety results
Tarcocimab tedromer
| Dropout rate | 8.3% NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 |
|---|---|
| Discontinued due to AEs | 2.9% NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 |
| Serious AEs | 14.1% NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 |
| Most frequent reported AEs | covid-19 12.3% neovascular age-related macular degeneration - fellow eye 8% vitreous floaters - study eye 7.6% NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Brolucizumab-Dbll's landscape · Tarcocimab tedromer's landscape